Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861999 | 1.00 | NPY5R (0.63) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL2652609 | 1.00 | NPY5R (0.63) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL1107401 | 0.84 | NPY5R (0.70) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL2645649 | 0.84 | NPY5R (0.70) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL1859968 | 0.83 | NPY5R (0.68) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL1859971 | 0.83 | NPY5R (0.68) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL2668153 | 0.83 | NPY5R (0.53) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL8153290 | 0.83 | NPY5R (0.78) | NPY5RGAAOPRK1CYP2D6CYP3A4 | |
| SCHEMBL2668110 | 0.81 | NPY5R (0.43) | NPY5ROPRK1CYP2D6CYP3A4TSHR | |
| SCHEMBL14285930 | 0.81 | GAA (0.48) | NPY5RGAACCR5KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059522-B1 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| EP-1789396-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Prosidion Limited (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007051847-A1 | TRICYCLO SUBSTITUTED AMIDES AS GLUCOKINASE MODULATORS | PROSIDION LTD (GB) | 2007-05-10 | — | — | WO | disclosed |
| EP-1740560-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | Prosidion Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006016194-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118211-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, MPO, GCK | NPY5R 1779/4885GAA 750/4885OPRK1 849/4885 |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | GCK, KHK, GCKR | NPY5R 3624/4885GAA 254/4885OPRK1 3409/4885 |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | NPY5R 1688/4885GAA 810/4885OPRK1 785/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | NPY5R 1676/4885GAA 1023/4885OPRK1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.